PRESS RELEASE Alexandria, Va viagra pills ., March 6, 2015 – Today’s authorization of the U.S.’s initial biosimilar is an important part of increasing access to life-saving and life-improving biologics, but it is just a first step, AMCP CEO Edith A. Rosato, RPh, IOM, stated in response to the Food and Drug Administration’ s action today. Much work must be done to promote their use and acceptance. The FDA should next end the heated debate over biosimilars naming and require that biosimilars and their branded biologic counterparts share the same nonproprietary name. The FDA should also issue clear rules for designating a biosimilar product as interchangeable with a reference product.
AMCP Chief Executive Officer Edith A. Rosato, RPh, IOM, issued the next declaration: We support HHS’s initiatives to expand prescription medication monitoring programs and real-time data posting, as well as to better integrate information into electronic health records among health professionals. AMCP would encourage HHS to proceed even further by allowing health plans and other appropriate managed treatment stakeholders to get access to this information within a coordinated work to help patients and reduce the burden of opioid-related overdoses and dependency. Outside of HHS’s proposal latest, AMCP urges passage of legislation that would allow Medicare Part D and Medicare Benefit prescription drug programs to limit patients with a brief history of misuse to an individual prescriber and/or pharmacy , similar to what currently occurs in the private marketplace and the Medicaid program.